{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:14:32Z","timestamp":1783606472962,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.leukres.2026.108271","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:42:24Z","timestamp":1782229344000},"page":"108271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["FLAMSA versus FLAG-IDA as salvage therapy in adults with relapsed\/refractory acute myeloid leukemia and acute lymphoblastic leukemia: A single-center real-world retrospective study"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-9431","authenticated-orcid":false,"given":"Emine Merve","family":"Sava\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3858-5140","authenticated-orcid":false,"given":"Hale Hilal","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin I\u015f\u0131l","family":"Kemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyma","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcnevver \u0130rem K\u00f6k","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6082-2995","authenticated-orcid":false,"given":"Ahmet","family":"\u015eeyhanl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0212-9663","authenticated-orcid":false,"given":"Zeynep Arzu","family":"Ye\u011fin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M\u00fcnci","family":"Ya\u011fc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00fcbeyde Nur","family":"\u00d6zkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2026.108271_bib1","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000572","article-title":"Treatment for relapsed\/refractory acute myeloid leukemia","volume":"5","author":"Thol","year":"2021","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.leukres.2026.108271_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2023022481","article-title":"How I treat refractory and relapsed acute myeloid leukemia","volume":"143","author":"Thol","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2026.108271_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-016-0519-8","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia in adults","volume":"18","author":"Ronson","year":"2016","journal-title":"Curr. Oncol. Rep."},{"issue":"30","key":"10.1016\/j.leukres.2026.108271_bib4","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2010.28.6856","article-title":"Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A","volume":"28","author":"Schlenk","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108271_bib5","first-page":"2032","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"19","key":"10.1016\/j.leukres.2026.108271_bib6","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1158\/1078-0432.CCR-22-0809","article-title":"Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: an ALWP\/EBMT analysis","volume":"28","author":"Nagler","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.leukres.2026.108271_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V80.4.1090.1090","article-title":"Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108271_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2991\/chi.d.191128.001","article-title":"Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia","volume":"2","author":"Popescu","year":"2020","journal-title":"Clin. Hematol. Int."},{"issue":"12","key":"10.1016\/j.leukres.2026.108271_bib9","first-page":"1345","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108271_bib10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.leukres.2026.108271_bib11","first-page":"1703","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108271_bib12","first-page":"1216","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer Interdisciplinary International Journal American Cancer Society"},{"issue":"1","key":"10.1016\/j.leukres.2026.108271_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-8588(05)70204-5","article-title":"Salvage therapy for refractory or relapsed acute lymphocytic leukemia","volume":"15","author":"Garcia-Manero","year":"2001","journal-title":"Hematol. \/Oncol. Clin. North. Am."},{"issue":"7","key":"10.1016\/j.leukres.2026.108271_bib14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review","volume":"97","author":"Meg\u00edas-Vericat","year":"2018","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108271_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/leu.2014.242","article-title":"Resistance prediction in AML: analysis of 4601 patients from MRC\/NCRI, HOVON\/SAKK, SWOG and MD Anderson Cancer Center","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2026.108271_bib16","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/j.clml.2024.12.016","article-title":"Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic Leukemia","volume":"25","author":"Jabbour","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.leukres.2026.108271_bib17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2026.108271_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00277-005-1090-9","article-title":"FLAG-IDA in the treatment of refractory\/relapsed adult acute lymphoblastic leukemia","volume":"84","author":"Specchia","year":"2005","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108271_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00277-003-0624-2","article-title":"FLAG-IDA in the treatment of refractory\/relapsed acute myeloid leukemia: single-center experience","volume":"82","author":"Pastore","year":"2003","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2026.108271_bib20","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00277-020-04131-1","article-title":"The FLAMSA concept\u2014past and future","volume":"99","author":"Kolb","year":"2020","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108271_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/10428194.2012.713479","article-title":"Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse","volume":"54","author":"Fong","year":"2013","journal-title":"Leuk. & Lymphoma"},{"issue":"11","key":"10.1016\/j.leukres.2026.108271_bib22","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0145-2126(86)90331-0","article-title":"Amsacrine: a review","volume":"10","author":"Cassileth","year":"1986","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2026.108271_bib23","first-page":"317","article-title":"Treatment of acute leukemia in relapse with 4\u2032(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine","volume":"4","author":"Arlin","year":"1981","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108271_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1987.5.3.371","article-title":"A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia","volume":"5","author":"Arlin","year":"1987","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2026.108271_bib25","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108271_bib26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1080\/10428194.2018.1508670","article-title":"FLAG salvage therapy combined with idarubicin in relapsed\/refractory acute myeloid leukemia","volume":"60","author":"Westhus","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2026.108271_bib27","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/j.clml.2021.02.007","article-title":"Retrospective Analysis of Adult Patients With Relapsed\/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center","volume":"21","author":"Tenold","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.leukres.2026.108271_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mjt.0000181690.21601.09","article-title":"IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience","volume":"13","author":"Yavuz","year":"2006","journal-title":"Am. J. Ther."},{"issue":"2","key":"10.1016\/j.leukres.2026.108271_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.V72.2.433.bloodjournal722433","article-title":"Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults","volume":"72","author":"Arlin","year":"1988","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108271_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29997","article-title":"Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial","volume":"69","author":"Mezger","year":"2022","journal-title":"Pediatr. Blood & Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:21:46Z","timestamp":1783603306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"alternative-id":["S0145212626001153"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108271","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLAMSA versus FLAG-IDA as salvage therapy in adults with relapsed\/refractory acute myeloid leukemia and acute lymphoblastic leukemia: A single-center real-world retrospective study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108271"}}